Time-restricted eating (TRE) is safe and feasible for weight management but offers no additional benefits over a Mediterranean diet for reducing visceral fat. Early TRE shows promise in reducing subcutaneous fat and improving fasting glucose levels.
Boston Scientific raises full-year forecast again, fueled by strong Q2
By the numbers Q2 Net sales: $3.6 billion 11% increase year-over-year Q2 Net income: $261 million 6% increase year-over-year Q2 Earnings per share: $0.18 6%